Jashodeep Datta, a researcher with Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, has been awarded a grant from the U.S. Department of Defense’s Congressionally Directed Medical Research Program to target chemotherapy resistance in pancreatic cancer. The $800,000, three-year grant is the first DoD award to Sylvester to study pancreatic cancer.
Zoldonrasib, an oral RAS(ON) G12D-selective covalent inhibitor, in combination with daraxonrasib showed 81% objective response rate compared to zoldonrasib in combination with standard of care chemotherapy in previously untreated patients with RAS G12D metastatic pancreatic ductal adenocarcinoma, according to results of two phase I/II study.
